The clinical features of older patients with lung cancer in comparison with their younger counterparts
Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them. The patients wit...
Gespeichert in:
Veröffentlicht in: | Respiratory investigation 2019-01, Vol.57 (1), p.40-48 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 48 |
---|---|
container_issue | 1 |
container_start_page | 40 |
container_title | Respiratory investigation |
container_volume | 57 |
creator | Ogino, Hirokazu Hanibuchi, Masaki Sakaguchi, Satoshi Toyoda, Yuko Tezuka, Toshifumi Kawano, Hiroshi Kakiuchi, Soji Otsuka, Kenji Saijo, Atsuro Azuma, Masahiko Nokihara, Hiroshi Goto, Hisatsugu Nishioka, Yasuhiko |
description | Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them.
The patients with lung cancer who were admitted to our hospital between April 1, 2012 and March 31, 2015 were retrospectively analyzed. Patients older than 75 years were defined as older patients. Standard treatments were based on the guidelines.
In total, 333 patients were analyzed. The older patients had a poor performance status (PS), more comorbidities, and fewer opportunities to receive standard treatments. The prognosis of the older patients who received standard treatments was superior to that of those who did not. The therapeutic efficacy of standard treatments for older patients with stages I and II diseases was similar to their younger counterparts. However, the prognosis of older patients with advanced stage, especially stage III disease, was poor. The tolerability of first-line chemotherapy by older patients was comparable with their younger counterparts, but the older patients had fewer opportunities to receive several chemotherapy regimens, even second line chemotherapy.
We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification. |
doi_str_mv | 10.1016/j.resinv.2018.10.003 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2135635433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212534518301102</els_id><sourcerecordid>2135635433</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-80468d5e907009a9f1443bd5afbfd8d05b8dcbadf0e23f94ce0ec9e7965bbb243</originalsourceid><addsrcrecordid>eNp9kE1LxDAQQIMoruj-A5EcvbQmTdJtL4KIXyB40XNIk4mbpW3WJFX892bp6tFcJsy8mWEeQueUlJTQ-mpTBohu_CwrQpucKglhB-ikqmhVCCbY4d-fiwVaxrgh-dWi4rQ-RgtGOG8qzk6QfV0D1r0bnVY9tqDSlCdjb7HvDQS8VcnBmCL-cmmN-2l8x1qNOlfciLUftiq46Me5nNbgAv72mcqAzjFByESKZ-jIqj7Cch9P0dv93evtY_H88vB0e_NcaNbUqWgIrxsjoCUrQlrVWso564xQtrOmMUR0jdGdMpZAxWzLNRDQLazaWnRdlw86RZfz3G3wHxPEJAcXNfS9GsFPUVaUiZoJzlhG-Yzq4GMMYOU2uEGFb0mJ3EmWGzlLljvJu2yWnNsu9humbgDz1_SrNAPXMwD5zk8HQUadFWowLoBO0nj3_4Yf6CWRxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2135635433</pqid></control><display><type>article</type><title>The clinical features of older patients with lung cancer in comparison with their younger counterparts</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ogino, Hirokazu ; Hanibuchi, Masaki ; Sakaguchi, Satoshi ; Toyoda, Yuko ; Tezuka, Toshifumi ; Kawano, Hiroshi ; Kakiuchi, Soji ; Otsuka, Kenji ; Saijo, Atsuro ; Azuma, Masahiko ; Nokihara, Hiroshi ; Goto, Hisatsugu ; Nishioka, Yasuhiko</creator><creatorcontrib>Ogino, Hirokazu ; Hanibuchi, Masaki ; Sakaguchi, Satoshi ; Toyoda, Yuko ; Tezuka, Toshifumi ; Kawano, Hiroshi ; Kakiuchi, Soji ; Otsuka, Kenji ; Saijo, Atsuro ; Azuma, Masahiko ; Nokihara, Hiroshi ; Goto, Hisatsugu ; Nishioka, Yasuhiko</creatorcontrib><description>Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them.
The patients with lung cancer who were admitted to our hospital between April 1, 2012 and March 31, 2015 were retrospectively analyzed. Patients older than 75 years were defined as older patients. Standard treatments were based on the guidelines.
In total, 333 patients were analyzed. The older patients had a poor performance status (PS), more comorbidities, and fewer opportunities to receive standard treatments. The prognosis of the older patients who received standard treatments was superior to that of those who did not. The therapeutic efficacy of standard treatments for older patients with stages I and II diseases was similar to their younger counterparts. However, the prognosis of older patients with advanced stage, especially stage III disease, was poor. The tolerability of first-line chemotherapy by older patients was comparable with their younger counterparts, but the older patients had fewer opportunities to receive several chemotherapy regimens, even second line chemotherapy.
We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification.</description><identifier>ISSN: 2212-5345</identifier><identifier>EISSN: 2212-5353</identifier><identifier>DOI: 10.1016/j.resinv.2018.10.003</identifier><identifier>PMID: 30448243</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Age Factors ; Aged ; Chemoradiotherapy ; Comorbidity ; Drug Therapy ; Female ; Humans ; Life Expectancy ; Lung cancer ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Middle Aged ; Neoplasm Staging ; Older patients ; Prognosis ; Real-world clinical practice ; Retrospective Studies ; Standard treatments ; Survival Rate ; Treatment Outcome</subject><ispartof>Respiratory investigation, 2019-01, Vol.57 (1), p.40-48</ispartof><rights>2018 The Japanese Respiratory Society</rights><rights>Copyright © 2018 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-80468d5e907009a9f1443bd5afbfd8d05b8dcbadf0e23f94ce0ec9e7965bbb243</citedby><cites>FETCH-LOGICAL-c386t-80468d5e907009a9f1443bd5afbfd8d05b8dcbadf0e23f94ce0ec9e7965bbb243</cites><orcidid>0000-0002-4637-9488 ; 0000-0002-7710-5498</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30448243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogino, Hirokazu</creatorcontrib><creatorcontrib>Hanibuchi, Masaki</creatorcontrib><creatorcontrib>Sakaguchi, Satoshi</creatorcontrib><creatorcontrib>Toyoda, Yuko</creatorcontrib><creatorcontrib>Tezuka, Toshifumi</creatorcontrib><creatorcontrib>Kawano, Hiroshi</creatorcontrib><creatorcontrib>Kakiuchi, Soji</creatorcontrib><creatorcontrib>Otsuka, Kenji</creatorcontrib><creatorcontrib>Saijo, Atsuro</creatorcontrib><creatorcontrib>Azuma, Masahiko</creatorcontrib><creatorcontrib>Nokihara, Hiroshi</creatorcontrib><creatorcontrib>Goto, Hisatsugu</creatorcontrib><creatorcontrib>Nishioka, Yasuhiko</creatorcontrib><title>The clinical features of older patients with lung cancer in comparison with their younger counterparts</title><title>Respiratory investigation</title><addtitle>Respir Investig</addtitle><description>Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them.
The patients with lung cancer who were admitted to our hospital between April 1, 2012 and March 31, 2015 were retrospectively analyzed. Patients older than 75 years were defined as older patients. Standard treatments were based on the guidelines.
In total, 333 patients were analyzed. The older patients had a poor performance status (PS), more comorbidities, and fewer opportunities to receive standard treatments. The prognosis of the older patients who received standard treatments was superior to that of those who did not. The therapeutic efficacy of standard treatments for older patients with stages I and II diseases was similar to their younger counterparts. However, the prognosis of older patients with advanced stage, especially stage III disease, was poor. The tolerability of first-line chemotherapy by older patients was comparable with their younger counterparts, but the older patients had fewer opportunities to receive several chemotherapy regimens, even second line chemotherapy.
We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Chemoradiotherapy</subject><subject>Comorbidity</subject><subject>Drug Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Life Expectancy</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Older patients</subject><subject>Prognosis</subject><subject>Real-world clinical practice</subject><subject>Retrospective Studies</subject><subject>Standard treatments</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>2212-5345</issn><issn>2212-5353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQQIMoruj-A5EcvbQmTdJtL4KIXyB40XNIk4mbpW3WJFX892bp6tFcJsy8mWEeQueUlJTQ-mpTBohu_CwrQpucKglhB-ikqmhVCCbY4d-fiwVaxrgh-dWi4rQ-RgtGOG8qzk6QfV0D1r0bnVY9tqDSlCdjb7HvDQS8VcnBmCL-cmmN-2l8x1qNOlfciLUftiq46Me5nNbgAv72mcqAzjFByESKZ-jIqj7Cch9P0dv93evtY_H88vB0e_NcaNbUqWgIrxsjoCUrQlrVWso564xQtrOmMUR0jdGdMpZAxWzLNRDQLazaWnRdlw86RZfz3G3wHxPEJAcXNfS9GsFPUVaUiZoJzlhG-Yzq4GMMYOU2uEGFb0mJ3EmWGzlLljvJu2yWnNsu9humbgDz1_SrNAPXMwD5zk8HQUadFWowLoBO0nj3_4Yf6CWRxw</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Ogino, Hirokazu</creator><creator>Hanibuchi, Masaki</creator><creator>Sakaguchi, Satoshi</creator><creator>Toyoda, Yuko</creator><creator>Tezuka, Toshifumi</creator><creator>Kawano, Hiroshi</creator><creator>Kakiuchi, Soji</creator><creator>Otsuka, Kenji</creator><creator>Saijo, Atsuro</creator><creator>Azuma, Masahiko</creator><creator>Nokihara, Hiroshi</creator><creator>Goto, Hisatsugu</creator><creator>Nishioka, Yasuhiko</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4637-9488</orcidid><orcidid>https://orcid.org/0000-0002-7710-5498</orcidid></search><sort><creationdate>201901</creationdate><title>The clinical features of older patients with lung cancer in comparison with their younger counterparts</title><author>Ogino, Hirokazu ; Hanibuchi, Masaki ; Sakaguchi, Satoshi ; Toyoda, Yuko ; Tezuka, Toshifumi ; Kawano, Hiroshi ; Kakiuchi, Soji ; Otsuka, Kenji ; Saijo, Atsuro ; Azuma, Masahiko ; Nokihara, Hiroshi ; Goto, Hisatsugu ; Nishioka, Yasuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-80468d5e907009a9f1443bd5afbfd8d05b8dcbadf0e23f94ce0ec9e7965bbb243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Chemoradiotherapy</topic><topic>Comorbidity</topic><topic>Drug Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Life Expectancy</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Older patients</topic><topic>Prognosis</topic><topic>Real-world clinical practice</topic><topic>Retrospective Studies</topic><topic>Standard treatments</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogino, Hirokazu</creatorcontrib><creatorcontrib>Hanibuchi, Masaki</creatorcontrib><creatorcontrib>Sakaguchi, Satoshi</creatorcontrib><creatorcontrib>Toyoda, Yuko</creatorcontrib><creatorcontrib>Tezuka, Toshifumi</creatorcontrib><creatorcontrib>Kawano, Hiroshi</creatorcontrib><creatorcontrib>Kakiuchi, Soji</creatorcontrib><creatorcontrib>Otsuka, Kenji</creatorcontrib><creatorcontrib>Saijo, Atsuro</creatorcontrib><creatorcontrib>Azuma, Masahiko</creatorcontrib><creatorcontrib>Nokihara, Hiroshi</creatorcontrib><creatorcontrib>Goto, Hisatsugu</creatorcontrib><creatorcontrib>Nishioka, Yasuhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogino, Hirokazu</au><au>Hanibuchi, Masaki</au><au>Sakaguchi, Satoshi</au><au>Toyoda, Yuko</au><au>Tezuka, Toshifumi</au><au>Kawano, Hiroshi</au><au>Kakiuchi, Soji</au><au>Otsuka, Kenji</au><au>Saijo, Atsuro</au><au>Azuma, Masahiko</au><au>Nokihara, Hiroshi</au><au>Goto, Hisatsugu</au><au>Nishioka, Yasuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical features of older patients with lung cancer in comparison with their younger counterparts</atitle><jtitle>Respiratory investigation</jtitle><addtitle>Respir Investig</addtitle><date>2019-01</date><risdate>2019</risdate><volume>57</volume><issue>1</issue><spage>40</spage><epage>48</epage><pages>40-48</pages><issn>2212-5345</issn><eissn>2212-5353</eissn><abstract>Older patients with lung cancer have increased over the past decades. Several standard treatments for older patients were established, but their clinical features in real world clinics remain unknown. Thus, we performed a retrospective study to clarify the clinical features of them.
The patients with lung cancer who were admitted to our hospital between April 1, 2012 and March 31, 2015 were retrospectively analyzed. Patients older than 75 years were defined as older patients. Standard treatments were based on the guidelines.
In total, 333 patients were analyzed. The older patients had a poor performance status (PS), more comorbidities, and fewer opportunities to receive standard treatments. The prognosis of the older patients who received standard treatments was superior to that of those who did not. The therapeutic efficacy of standard treatments for older patients with stages I and II diseases was similar to their younger counterparts. However, the prognosis of older patients with advanced stage, especially stage III disease, was poor. The tolerability of first-line chemotherapy by older patients was comparable with their younger counterparts, but the older patients had fewer opportunities to receive several chemotherapy regimens, even second line chemotherapy.
We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30448243</pmid><doi>10.1016/j.resinv.2018.10.003</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4637-9488</orcidid><orcidid>https://orcid.org/0000-0002-7710-5498</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2212-5345 |
ispartof | Respiratory investigation, 2019-01, Vol.57 (1), p.40-48 |
issn | 2212-5345 2212-5353 |
language | eng |
recordid | cdi_proquest_miscellaneous_2135635433 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Adult Age Factors Aged Chemoradiotherapy Comorbidity Drug Therapy Female Humans Life Expectancy Lung cancer Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy Male Middle Aged Neoplasm Staging Older patients Prognosis Real-world clinical practice Retrospective Studies Standard treatments Survival Rate Treatment Outcome |
title | The clinical features of older patients with lung cancer in comparison with their younger counterparts |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T15%3A23%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20features%20of%20older%20patients%20with%20lung%20cancer%20in%20comparison%20with%20their%20younger%20counterparts&rft.jtitle=Respiratory%20investigation&rft.au=Ogino,%20Hirokazu&rft.date=2019-01&rft.volume=57&rft.issue=1&rft.spage=40&rft.epage=48&rft.pages=40-48&rft.issn=2212-5345&rft.eissn=2212-5353&rft_id=info:doi/10.1016/j.resinv.2018.10.003&rft_dat=%3Cproquest_cross%3E2135635433%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2135635433&rft_id=info:pmid/30448243&rft_els_id=S2212534518301102&rfr_iscdi=true |